awmsg logo



doxylamine succinate/pyridoxine hydrochloride (Xonvea®)


Reference No. 2170

Publication date:
12/06/2019


Appraisal information

doxylamine succinate/pyridoxine hydrochloride (Xonvea®) 10 mg/10 mg film-coated tablet


Company: Alliance Pharmaceuticals Ltd
BNF category: Central nervous system
NMG meeting date: 03/04/2019
AWMSG meeting date: 15/05/2019
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 0819
Ratification by Welsh Government: 11/06/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Doxylamine succinate/pyridoxine hydrochloride (Xonvea®) is not recommended for use within NHS Wales for the treatment of nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management. The cost-effectiveness data presented in the submission were insufficient for AWMSG to recommend its use.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download